Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome

Preetesh Jain, Sa Wang, Keyur P. Patel, Nawid Sarwari, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

Mast cell leukemia (MCL) is a very rare subtype of systemic mastocytosis (SM). We have identified 13 such patients (5.9%) among 218 patients with SM seen at our institution between 1994 and 2016. Patients with MCL had poor survival (median 31.6 months); response to various therapies was rare and not durable. Clinical course may be affected by concurrent associated hematologic neoplasm and different genetic profiles. More research is required to decipher this rare and enigmatic SM subtype.

Original languageEnglish (US)
Pages (from-to)105-109
Number of pages5
JournalLeukemia Research
Volume59
DOIs
StatePublished - Aug 2017

Fingerprint

Mast-Cell Leukemia
Systemic Mastocytosis
Survival
Hematologic Neoplasms
Research
Therapeutics

Keywords

  • Mast cell leukemia
  • Systemic mastocytosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Mast cell leukemia (MCL) : Clinico-pathologic and molecular features and survival outcome. / Jain, Preetesh; Wang, Sa; Patel, Keyur P.; Sarwari, Nawid; Cortes, Jorge; Kantarjian, Hagop; Verstovsek, Srdan.

In: Leukemia Research, Vol. 59, 08.2017, p. 105-109.

Research output: Contribution to journalArticle

Jain, Preetesh ; Wang, Sa ; Patel, Keyur P. ; Sarwari, Nawid ; Cortes, Jorge ; Kantarjian, Hagop ; Verstovsek, Srdan. / Mast cell leukemia (MCL) : Clinico-pathologic and molecular features and survival outcome. In: Leukemia Research. 2017 ; Vol. 59. pp. 105-109.
@article{6bce52d7e45f497bafcdd2fb2afbeb8d,
title = "Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome",
abstract = "Mast cell leukemia (MCL) is a very rare subtype of systemic mastocytosis (SM). We have identified 13 such patients (5.9{\%}) among 218 patients with SM seen at our institution between 1994 and 2016. Patients with MCL had poor survival (median 31.6 months); response to various therapies was rare and not durable. Clinical course may be affected by concurrent associated hematologic neoplasm and different genetic profiles. More research is required to decipher this rare and enigmatic SM subtype.",
keywords = "Mast cell leukemia, Systemic mastocytosis",
author = "Preetesh Jain and Sa Wang and Patel, {Keyur P.} and Nawid Sarwari and Jorge Cortes and Hagop Kantarjian and Srdan Verstovsek",
year = "2017",
month = "8",
doi = "10.1016/j.leukres.2017.05.018",
language = "English (US)",
volume = "59",
pages = "105--109",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Mast cell leukemia (MCL)

T2 - Clinico-pathologic and molecular features and survival outcome

AU - Jain, Preetesh

AU - Wang, Sa

AU - Patel, Keyur P.

AU - Sarwari, Nawid

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

PY - 2017/8

Y1 - 2017/8

N2 - Mast cell leukemia (MCL) is a very rare subtype of systemic mastocytosis (SM). We have identified 13 such patients (5.9%) among 218 patients with SM seen at our institution between 1994 and 2016. Patients with MCL had poor survival (median 31.6 months); response to various therapies was rare and not durable. Clinical course may be affected by concurrent associated hematologic neoplasm and different genetic profiles. More research is required to decipher this rare and enigmatic SM subtype.

AB - Mast cell leukemia (MCL) is a very rare subtype of systemic mastocytosis (SM). We have identified 13 such patients (5.9%) among 218 patients with SM seen at our institution between 1994 and 2016. Patients with MCL had poor survival (median 31.6 months); response to various therapies was rare and not durable. Clinical course may be affected by concurrent associated hematologic neoplasm and different genetic profiles. More research is required to decipher this rare and enigmatic SM subtype.

KW - Mast cell leukemia

KW - Systemic mastocytosis

UR - http://www.scopus.com/inward/record.url?scp=85020240266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020240266&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2017.05.018

DO - 10.1016/j.leukres.2017.05.018

M3 - Article

C2 - 28599188

AN - SCOPUS:85020240266

VL - 59

SP - 105

EP - 109

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -